Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03206021
Other study ID # OZM-077
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 1, 2017
Est. completion date March 1, 2024

Study information

Verified date April 2024
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all recurrent/refractory pediatric brain and solid tumors. The phase I component will establish with maximum tolerated dose of carboplatin with azacytidine. An expansion cohort will be recruited of up to 30 patients will follow consisting of 20 recurrent posterior fossa ependymoma and 10 recurrent supratentorial ependymoma.


Description:

Aberrant DNA methylation is frequently observed in many pediatric solid tumors, but in particularly several entities such as ependymoma, medulloblastoma, embryonal tumor with multilayered rosettes, atypical/teratoid rhabdoid tumor, neuroblastoma and wilm's tumor have promoter hypermethylation. Treatment with DNMTi (DNA methyltransferase inhibitors) agents such as 5-azacytidine has been shown to be safe and efficacious in adult myelodysplastic syndromes, causing significant decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. However, monotherapy with DNMTi has been shown to result in resistance in leukamia's and efficacy in solid tumours is limited. Synergy between DNMTi and platinum agents has shown promise in pre-clinical models including pediatric ependymoma, and in addition, the combination of demethylating agents with carboplatin has provided promising results in platinum resistant ovarian cancers. However, this approach has not been applied to pediatric solid malignancies, which are attractive targets due to their frequent epigenetic dysregulation. Platinums are the backbone of therapy for most pediatric solid tumors, and as such it is an attractive hypothesis that part of the reason for resistance to upfront therapies is platinum resistance. Specifically, ependymoma's are highly chemoresistant tumors and studies in preclinical models of ependymoma support that this chemoresistance can be overcome with DNMTi. There is a clear medical need for new therapies, particularly for relapsed solid tumors, specifically brain tumors. Although pre-clinical data from our group and others suggests DNA demethylase inhibitors to be promising therapies for high risk ependymoma, medulloblastoma and ETMR (embryonal tumor with multilayered rosettes), 5'azacitidine monotherapy has been disappointing in clinical studies of adult solid tumours. Previous studies have suggested that platinum therapy can be effectively combined with azacitidine therapy and based on adult studies, maximum demethylation occurs approximately 5-10 days after treatment with 5'azacitidine. As such combination of azacitidine and carboplatin is a rationale therapy for several pediatric brain tumours, particularly those with a hypermethylated phenotype. Two phases of the study will be conducted. The Phase I will establish the maximum tolerated dose of carboplatin and 5'azacytidine in a rolling 6 design. 5'azacytidine will be administered on Days 1-7 followed by Carboplatin on Day 15. The initial dose level will be 5'Azacytidine 75mg/m2/day for 7 days with Carboplatin administered on Day 15 at AUC (Area under curve) 4. Carboplatin will be dose escalated to a maximum of AUC 6, or de-escalated to AUC 3. The Phase Ib will be an ependymoma specific expansion cohort at the established MTD (maximum tolerated dose), to determine the feasibility and initial efficacy of the combination of carboplatin and 5'azacytidine in patients with recurrent/refractory posterior fossa and supratentorial ependymoma.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date March 1, 2024
Est. primary completion date August 31, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: 1. Greater than the age of 1 year and under age 18 at the time of study enrolment 2. Recurrent or refractory brain or solid tumor, including recurrent or refractory ependymoma 3. Tissue from diagnosis or resection prior to registration must be available (either flash frozen tissue or an FFPE block) 4. Previous therapy with carboplatin will be permitted 5. Failed first line treatment (surgery, radiation therapy or chemotherapy) and should not be eligible for treatment with curative potential. 6. Be at least 4 weeks from the completion of myelosuppressive chemotherapy and/or biologic agents before starting day 1 of this study treatment 7. Be at least 14 days from the completion of radiation therapy and MIBG before starting day 1 of this study treatment 8. Be at least 3 months post hematopoetic stem cell rescue following myeloablative therapy before starting day 1 of this study treatment 9. Must have visible disease on imaging. Resection of visible disease is permitted while on study after two cycles including achievement of a gross total resection. If a resection is performed while on study, fresh frozen tissue should be submitted for analysis. 10. Concurrent medications will be limited to supportive medications/agents including but not limited to anti-emetics, steroids, analgesics and non-enzyme inducing anticonvulsants. Strong inducers of the P450 system will not be permitted. Other concurrent medications require approval of the study Sponsor. 11. Ability of the parent and/or child to understand and the willingness to sign a written informed consent document 12. Karnofsky = 50 for patients > 16 years of age and Lansky = 50 for patients = 16 years of age (See Appendix I for the Karnofsky-Lansky Scores). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. Patients with posterior fossa syndrome/cerebellar mutism demonstrating clear improvement post-surgically can be enrolled based on physician discretion 13. Adequate hepatic, renal, marrow and cardiac function as defined below within 28 days prior to cycle 1 day 1: - Serum creatinine within normal institutional limits or creatinine clearance greater than 60mL/min - Serum bilirubin <1.5 times upper limit of institutional normal. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis - AST, ALT and Alkaline Phosphatase <3 times upper limit of institutional normal. If liver metastases are present, then <5 times upper limit of normal is permitted. - Normal QTc interval at screening ECG (baseline echocardiogram is not required) - Adequate marrow function defined below within 14 days prior to cycle 1 day 1: - Leukocytes greater than or equal to 1000 x106/L - Absolute neutrophil count greater than or equal to 0.75 x109/L - Platelets greater than or equal to 75 x109/L - Hemoglobin greater than or equal to 10g/dL (may be transfused). Exclusion Criteria: 1. Female patient who is pregnant or breast feeding (Lactating females must agree not to breast feed while taking azacitidine) or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 6 months after the end of study treatment. 2. Patients may not be receiving any other investigational agents within 30 days prior to day 1 of protocol treatment 3. Prior therapy with a DNA demethylase inhibitor 4. Evidence of cardiac toxicity (shortening fraction below 28%; shortening fraction measures and ratios the change in the diameter of the left ventricle between the contracted and relaxed states) 5. Abnormal coagulation parameters (PT >15 seconds, PTT>40 seconds, and/or INR >1.5) 6. Significant active cardiac disease within the previous 6 months including: - NYHA class 3 or 4 CHF - Unstable angina - Myocardial infarction 7. Known or suspected hypersensitivity to azacitidine or mannitol carboplatin 8. Previous carboplatin exposure is not an exclusion criteria but previous allergic reaction to carboplatin will exclude enrolment. 9. Patient must not require use of enzyme inducing anticonvulsants; patients who are receiving an enzyme inducing anticonvulsant must be able to switch to a non-enzyme inducing anticonvulsant such as Levetiracetam, Clobazam, Lacosamide, Valproate or Topiramate at least 2 weeks prior to study enrolment. 10. Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment) 11. Active viral infection with HIV or hepatitis type B or C Patients with advanced malignant hepatic tumors 12. Patients with advanced malignant hepatic tumors

Study Design


Intervention

Drug:
5 Azacytidine
Dose escalation of carboplatin combined with 5'azacytidine

Locations

Country Name City State
Australia Women's and Children's Hospital Adelaide
Australia Monash Children's Hospital Clayton
Australia John Hunter Children's Hospital Lambton
Australia Royal Children's Hospital Melbourne Melbourne Victoria
Australia Perth Children's Hospital Perth
Australia Queensland Children's Hospital South Brisbane
Australia Sydney Children's Hospital Sydney
Australia Children's Hospital at Westmead Westmead
Canada Alberta Children's Hospital Calgary Alberta
Canada McMaster Children's Hospital Hamilton Ontario
Canada London Health Sciences Centre London Ontario
Canada Centre hospitalier universitaire Sainte-Justine Montréal PQ
Canada Montreal Children's Hospital Montréal PQ
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Canada Hospital for Sick Children Toronto Ontario
Canada BC Children's Hospital Vancouver British Columbia
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Countries where clinical trial is conducted

United States,  Australia,  Canada, 

References & Publications (2)

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, Wang X, Gallo M, Garzia L, Zayne K, Zhang X, Ramaswamy V, Jager N, Jones DT, Sill M, Pugh TJ, Ryzhova M, Wani KM, Shih DJ, Head R, Remke M, Bailey SD, Zichner T, Faria CC, Barszczyk M, Stark S, Seker — View Citation

Ramaswamy V, Hielscher T, Mack SC, Lassaletta A, Lin T, Pajtler KW, Jones DT, Luu B, Cavalli FM, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon RE, Lipp ES, Dunham C, Hukin J, Eisenstat DD, Fulton D, van Landeghem FK, Santi M, van Veele — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Establish maximum tolerated dose of carboplatin in combination with 5'azacytidine Number of participants with treatment-related adverse events as assessed by the CTCAE4.0 1 year
Secondary Characterization of the pharmacodynamics of 5'-azacitidine in combination with carboplatin Plasma pharmacodynamics will be assessed using methylation profiling of whole blood collected before and after administration of 5'Azacytidine, and after administration of carboplatin. 3 years
Secondary Assessment of intratumoral DNA demethylation as a preliminary indication of biological efficacy of this combination. Where feasible, two cycles of 5'azacytidine and carboplatin will be administered prior to a biopsy and/or gross total resection, and intratumoral DNA methylation profiles will be generated to determine the degree of intratumoral DNA demethylation. 3 years
Secondary Assessment of disease response as a preliminary indication of efficacy of this combination against recurrent, refractory pediatric brain and solid tumors Response to therapy, particularly in ependymoma will be evaluated to determine if a larger Phase II study is warranted. 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Completed NCT03430752 - Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia
Recruiting NCT01620372 - French Childhood Cancer Survivor Study N/A
Active, not recruiting NCT03585465 - Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Recruiting NCT01919866 - Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Phase 1/Phase 2
Terminated NCT01337544 - Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours Phase 1/Phase 2
Completed NCT02533895 - Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood Phase 1
Active, not recruiting NCT03445858 - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Early Phase 1
Recruiting NCT05504772 - Precision Medicine for Every Child With Cancer
Terminated NCT02624388 - Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Phase 2
Completed NCT01670175 - Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors Phase 1